Document Detail


Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine.
MedLine Citation:
PMID:  18030234     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To evaluate histological changes with interferon monotherapy or interferon plus lamivudine combination therapy in children with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. PATIENTS AND METHODS: 31 children aged 2-13 years were randomly treated with interferon (IFN) (group 1, n = 16) or IFN plus simultaneously started lamivudine (group 2, n = 15). IFN-alpha 2a was given 9 MU/m2 3 times per week for 6 months in each group; lamivudine was given 4 mg x kg(-1) x day(-1) for 24 months. Liver biopsy specimens were evaluated according to the Knodell score before therapy and after 24 months of therapy. Histological response was defined as a decrease in the histological activity index (HAI) score by at least 2 points. Efficacy of therapy was evaluated at 24 months of therapy in all children. RESULTS: Alanine aminotransferase normalization, HbeAg, and hepatitis B virus DNA clearance were not different. Complete response and histological response were 37.5%/62.5% and 40%/46.7% in groups 1 and 2, respectively (P = NS). At baseline and at 24 months of therapy, total HAI and components of HAI were not different in the 2 groups. In comparison with baseline, a significant decrease in scores of periportal +/- bridging necrosis was observed in group 1 (P = 0.01); periportal +/- bridging necrosis, intralobular degeneration, focal necrosis, and necroinflammation scores significantly decreased in group 2 (P = 0.04 and P = 0.02) at 24 months of therapy. CONCLUSIONS: The addition of lamivudine to IFN-alpha did not increase the effectiveness of the treatment in terms of complete and histological responses. Both therapies seemed to be effective in the regression of periportal +/- bridging necrosis. In addition, combination therapy was also effective in the regression of intralobular degeneration, focal necrosis, and necroinflammatory activity index.
Authors:
Zarife Kuloglu; Ceyda Tuna Krsaçloglu; Aydan Kansu; Esra Erden; Nurten Girgin
Related Documents :
20458844 - Effectiveness and tolerability of pegylated interferon alfa-2b in combination with riba...
8697164 - Long-term follow up of patients with dilated heart muscle disease treated with human le...
18482284 - Viral kinetic of hcv genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
17278224 - Recent i.v.-drug users with chronic hepatitis c can be efficiently treated with daily h...
14734334 - Management of adult patients with persistent idiopathic thrombocytopenic purpura follow...
2242974 - Emergency large-bowel surgery in a tropical environment: approach and outcome.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of pediatric gastroenterology and nutrition     Volume:  45     ISSN:  1536-4801     ISO Abbreviation:  J. Pediatr. Gastroenterol. Nutr.     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-11-21     Completed Date:  2008-01-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211545     Medline TA:  J Pediatr Gastroenterol Nutr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  564-8     Citation Subset:  IM    
Affiliation:
Department of Pediatric Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. zarifekuloglu@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anti-HIV Agents / therapeutic use*
Antiviral Agents / therapeutic use*
Biopsy
Child
Child, Preschool
Drug Therapy, Combination
Female
Follow-Up Studies
Hepatitis, Chronic / drug therapy*,  pathology
Humans
Interferon-alpha / therapeutic use*
Lamivudine / therapeutic use*
Liver / drug effects,  pathology*
Male
Necrosis
Prospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Antiviral Agents; 0/Interferon-alpha; 134678-17-4/Lamivudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Accuracy and tolerability of the Bravo catheter-free pH capsule in patients between the ages of 4 an...
Next Document:  Probiotics for necrotizing enterocolitis: a systematic review.